Skip to content

FP7H2020HORIZON

Universitaetsklinikum Freiburg

Country
DEGermany
Defence projects
0
Projects, all programmes
124
As coordinator
37
EU contribution (CORDIS)
EUR 64,486,497
Active
2008 to 2025

Projects

124 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
SCIDNETDevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID)H20202016ParticipantEUR 499,300
CIRDinnovaShifting the limits of resuscitation with “CIRD Controlled Integrated Resuscitation Device”H20202016CoordinatorEUR 369,702
CARATChimeric Antigen Receptors (CARs) for Advanced TherapiesH20202016ParticipantEUR 718,580
HEP-CARMechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities.H20202016CoordinatorEUR 771,550
RADAR-CNSRemote Assessment of Disease and Relapse in Central Nervous System DisordersH20202016ParticipantEUR 825,000
HBP SGA1Human Brain Project Specific Grant Agreement 1H20202016ParticipantEUR 0
GvHDCureUnderstanding the dynamics of the immune system to cure graft-versus-host disease (GvHD).H20202016CoordinatorEUR 1,987,500
BIO-CHIPBIOengineered grafts for Cartilage Healing In Patients (BIO-CHIP)H20202015ParticipantEUR 446,931
ApoptoMDSHematopoietic stem cell Apoptosis in bone marrow failure and MyeloDysplastic Syndromes: Friend or foe?H20202015CoordinatorEUR 1,372,525
ALKATRASALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancerH20202015ParticipantEUR 249,216
EUROPOLEUROPOLH20202015ParticipantEUR 498,433
EVAEVA - patient ventilation beyond limitsH20202015ParticipantEUR 621,250
MITOsmORFsIdentification and analysis of novel mitochondrial proteins encoded by small open reading framesH20202015CoordinatorEUR 1,094,166
COMBACTE-CARECombatting Bacterial Resistance in Europe - Carbapenem ResistanceFP72015ParticipantEUR 253,000
COMBACTE-MAGNETCombatting Bacterial Resistance in Europe - Molecules against Gram Negative InfectionsFP72015ParticipantEUR 471,150
GLYCOMARKERPROTEOMICS BASED IDENTIFICATION OF BIOMARKERS AND CLEAVAGE PRODUCTS IN PANCREATIC CANCER USING GLYCO-CAPTURE TECHNOLOGYH20202014CoordinatorEUR 161,969
FLAMMASECInflammasome-induced IL-1 Secretion: Route, Mechanism, and Cell FateFP72014CoordinatorEUR 541,716
DNCUREDynamic signalling networks in Diabetic Nephropathy (DN) – New avenues to a personalized therapy.-FP72014ParticipantEUR 1,259,489
COMBACTE-NETCombatting Bacterial Resistance in EuropeFP72013ParticipantEUR 509,217
RARE-BESTPRACTICESPlatform for sharing best practices for management of rare diseasesFP72013ParticipantEUR 176,200

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.